Colistin dampens fibrinolysis and endothelial activation during endotoxaemia

Summary

Colistin electrostatically interacts with lipopolysaccharides (LPS). Preclinical studies demonstrated beneficial effects of colistin on LPS-induced coagulation and fibrinolysis. The objective of this trial was to investigate the effects of colistin during experimental endotoxaemia. In this randomised, double-blind, placebo-controlled, crossover trial 16 healthy volunteers received a 2 ng/kg LPS bolus after infusion of 2.5 million IU colistin or placebo. Plasma levels of F1+2 prothrombin fragments, thrombin-antithrombin complexes (TAT), von Willebrand factor antigen levels (vWF), E-selectin, plasmin-antiplasmin complexes (PAP), tissue-type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor-1 (PAI-1) were measured. Infusion of colistin significantly reduced peak concentrations of PAP complexes by 70 %, t-PA antigen levels by 63 % and t-PA activity by 48 %, while PAI-1 levels decreased numerically by 63 %. Two hours after the LPS bolus F1+2 levels and TAT complexes were slightly reduced in the colistin period, but peak concentrations were similar in both periods. Colistin blunted the LPS induced four-fold increase in soluble E-Selectin levels by ∼50 % and the two-fold increase in vWF antigen levels by ∼70 %. The LPS-scavenging actions of colistin significantly reduce endothelial activation and fibrinolytic response in the human endotoxaemia model, while the activation of the coagulation system remains largely unaffected.

Note: This work was conducted at the Medical University of Vienna.

EudraCT-Nr.: 2014–00285720

Supplementary Material to this article is available online at http://www.thrombosis-online.com

Keywords

Coagulation - colistin - endotoxaemia - fibrinolysis - endothelial cells

• References

• 1 Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-1341.
• 2 Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol 2015; 71: 801-810.
• 3 Li J, Nation RL, Turnidge JD. et al. Colistin: the re-emerging antibiotic for multi-drug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 06: 589-601.
• 4 Herrmann G, Yang L, Wu H. et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aerugino-sa . J Infect Dis 2010; 202: 1585-1592.
• 5 Boisson M, Gregoire N, Couet W, Mimoz O. Colistin in critically ill patients. Minerva Anestesiol 2013; 79: 200-208.
• 6 Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979; 18: 4425-4430.
• 7 Koike M, Iida K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J Bacteriol 1969; 97: 448-452.
• 8 Aoki N, Tateda K, Kikuchi Y. et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas ae-ruginosa . J Antimicrob Chemother 2009; 63: 534-542.
• 9 Cirioni O, Ghiselli R, Orlando F. et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas ae-ruginosa strain. Crit Care Med 2007; 35: 1717-1723.
• 10 Corrigan Jr JJ, Bell BM. Comparison between the polymyxins and gentamicin in preventing endotoxin-induced intravascular coagulation and leukopenia. Infect Immun 1971; 04: 563-566.
• 11 Matzneller P, Gobin P, Lackner E, Zeitlinger M. Feasibility of microdialysis for determination of protein binding and target site pharmacokinetics of colistin in vivo. J Clin Pharmacol 2015; 55: 431-437.
• 12 Mayr FB, Jilma B. Coagulation interventions in experimental human endotoxaemia. Transl Res 2006; 148: 263-271.
• 13 Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W. et al. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999; 100: 2485-2490.
• 14 Dubor F, Dosne AM, Chedid LA. Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture. Infect Immun 1986; 52: 725-729.
• 15 Boos CJ, Mayr FB, Lip GY, Jilma B. Endotoxaemia enhances circulating endothelial cells in humans. J Thromb Haemost 2006; 04: 2509-2511.
• 16 van der Poll T, Coyle SM, Levi M. et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89: 3727-3734.
• 17 Hollenstein UM, Pernerstorfer T, Homoncik M. et al. Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis 2002; 186: 1270-1276.
• 18 Hollenstein U, Homoncik M, Stohlawetz PJ. et al. Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils. J Infect Dis 2000; 182: 343-346.
• 19 Suffredini AF, Fromm RE, Parker MM. et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-287.
• 20 Pernerstorfer T, Schmid R, Bieglmayer C. et al. Acetaminophen has greater antipyretic efficacy than aspirin in endotoxaemia: a randomized, double-blind, placebo-controlled trial. Clin Pharmacol Ther 1999; 66: 51-57.
• 21 Ruzicka K, Veitl M, Thalhammer-Scherrer R, Schwarzinger I. The new hematology analyzer Sysmex XE-2100: performance evaluation of a novel white blood cell differential technology. Arch Pathol Lab Med 2001; 125: 391-396.
• 22 Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME. et al. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 106: 539-547.
• 23 Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M. et al. Evaluation of antiin-flammatory and antiadhesive effects of heparins in human endotoxaemia. Crit Care Med 2003; 31: 1108-1112.
• 24 Spiel AO, Derhaschnig U, Schwameis M. et al. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin Sci 2012; 123: 591-600.
• 25 Mayr FB, Spiel AO, Leitner JM. et al. Racial differences in endotoxin-induced tissue factor-triggered coagulation. J Thromb Haemost 2009; 07: 634-640.
• 26 Matzneller P, Strommer S, Drucker C. et al. Colistin reduces LPS-triggered inflammation in a human sepsis model in vivo: A randomized controlled trial. Clin Pharmacol Ther. 2016 Epub ahead of print
• 27 Senturk S. Evaluation of the anti-endotoxic effects of polymyxin-E (colistin) in dogs with naturally occurred endotoxic shock. J Vet Pharmacol Ther 2005; 28: 57-63.
• 28 Warren HS, Kania SA, Siber GR. Binding and neutralisation of bacterial lipo-polysaccharide by colistin nonapeptide. Antimicrob Agents Chemother 1985; 28: 107-112.
• 29 Pajkrt D, Lerch PG, van der Poll T. et al. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxaemia. Thromb Haemost 1997; 77: 303-307.
• 30 Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipopro-teins and receptor-mediated endocytosis in the transport of bacterial lipopoly-saccharide. Proc Natl Acad Sci USA 1986; 83: 2704-2708.
• 31 Soon RL, Velkov T, Chiu F. et al. Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin-lipopolysaccharide binding interactions. Anal Biochem 2011; 409: 273-283.
• 32 Thaler B, Hohensinner PJ, Krychtiuk KA. et al. Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxaemia in humans. Sci Rep 2016; 06: 30162
• 33 Shimazu R, Akashi S, Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777-1782.
• 34 Lorne E, Dupont H, Abraham E. Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine?. Intensive Care Med 2010; 36: 1826-1835.
• 35 Mooberry MJ, Bradford R, Hobl EL. et al. Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxaemia. J Thromb Haemost 2016; 14: 1031-1042.
• 36 Semeraro N, Ammollo CT, Semeraro F, Colucci M. Coagulopathy of Acute Sepsis. Semin Thromb Hemost 2015; 41: 650-658.
• 37 Verbon A, Meijers JC, Spek CA. et al. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxaemia in humans. J Infect Dis 2003; 187: 55-61.
• 38 van Hinsbergh VW, Bauer KA, Kooistra T. et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76: 2284-2289.
• 39 de Jonge E, Dekkers PE, Creasey AA. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxaemia. Blood 2000; 95: 1124-1129.
• 40 Derhaschnig U, Bergmair D, Marsik C. et al. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxaemia. Crit Care Med 2004; 32: 1136-1140.
• 41 DeLa Cadena RA, Majluf-Cruz A, Stadnicki A. et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR: Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost 1998; 80: 114-118.
• 42 Laviola L, Orlando MR, Incalza MA. et al. TNFalpha signals via p66(Shc) to induce E-selectin, promote leukocyte transmigration and enhance permeability in human endothelial cells. PLoS One 2013; 08: e81930
• 43 Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002; 30 (Suppl. 05) S302-312.
• 44 Methia N, Andre P, Denis CV. et al. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98: 1424-1428.
• 45 Akca S, Haji-Michael P, de Mendonca A. et al. Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30: 753-756.
• 46 Schwameis M, Schorgenhofer C, Assinger A. et al. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015; 113: 708-718.
• 47 Kayal S, Jais JP, Aguini N. et al. Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am J Respir Crit Care Med 1998; 157: 776-784.
• 48 Iba T, Gando S, Murata A. et al. Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 2007; 63: 1093-1098.
• 49 Walley KR, Thain KR, Russell JA. et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med 2014; 06: 258ra143
• 50 van Deventer SJ, Buller HR, ten Cate JW. et al. Experimental endotoxaemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526.